BioScience VCT plc
26 July 2002
BIOSCIENCE VCT PLC
ISSUE OF EQUITY/ OFFERS CLOSE
BioScience VCT plc announces that on 12 June, 18 July and 23 July it issued and
allotted 306,021, 111,181 and 10,000 ordinary shares respectively under the
Offers for Subscription. The issued share capital of the Company is now
7,137,859 ordinary shares. The new shares were issued at a price of 100p each.
Application will be made at the earliest practicable opportunity for admission
of the new shares to trading on the Official List.
Dr Paul Nicholson, Chairman has subscribed for 10,000 shares and Mr Charles
Breese, Director, has subscribed for 5,000 shares under the Offers, representing
0.14% and 0.07% of the issued share capital.
The Offers for Subscription dated 17 October 2001 are closed with effect from
today. The Company has issued and allotted a total of 7,137,859 ordinary shares
under the Offers and has received a total of £7,061,339.46 before expenses.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.